Global Hemorrhagic Septicemia Vaccines Market 2026 – 2035

The global hemorrhagic septicemia (HS) vaccines market is projected to reach USD 0.39 billion in 2026, and is expected to climb at a CAGR of 4.6% from 2026 to 2035, reaching USD 0.57 billion by 2035. The high and recurring disease burden in endemic livestock populations in South Asia and Sub-Saharan Africa, the increasing national animal health spend by governments aiming to mitigate livestock mortality and the associated downstream economic consequences to agricultural GDP, and the evolving vaccine formulation technology, in particular based on oil adjuvants, which allow for prolonging the duration of immunity and decreasing the need for annual revaccination campaigns for herd-level protection, are all supporting market expansion.

Market Highlights

• Asia Pacific accounted for the largest market share at around 58% in 2025 due to its status as the major endemic area of Pasteurella multocida serotype B:2, the Asian serotype that causes the most economically damaging outbreaks and the large cattle and buffalo population densities in India, Bangladesh, Myanmar, Sri Lanka, Vietnam, Indonesia and the Philippines that represent the core addressable herd base for HS vaccination programs.

• Asia Pacific is also the fastest-growing regional market, which is expected to show a CAGR of around 5.8% from 2026 to 2035, owing to the growing government initiatives to vaccinate large populations, the growing costs of veterinary healthcare in the rapidly expanding livestock sector, and the growing awareness on the part of livestock farmers of the ROI argument for HS vaccination programs rather than the catastrophic impact of acute HS outbreaks on the economy, where mortality rates can be as high as 50–100% of the animals that are exposed within 24–48 hours of clinical symptoms appearing.

• The oil-adjuvant inactivated vaccine segment accounted for about 47% of total market revenue in 2025, a vaccine type that has been shown to provide a longer duration of immunity than the alum-precipitated bacterins; oil-adjuvant vaccines provide immunity for approximately 12 months per dose compared to 6–9 months for alum-precipitated bacterins, a duration advantage that is significant commercially when planning government vaccination campaigns and in remote livestock production systems, where the logistics of revaccinating the herd is costly.

• By vaccine type, live attenuated vaccine is growing at the highest compound annual growth rate (CAGR) of around 6.4% over the forecast period, owing to the attractive operational benefits of intranasal and oral delivery platforms, which have no animal handling associated with vaccine injection, fewer adverse injection site reactions, and are ideally suited to mass vaccination of buffalo herds in smallholder farming systems in South and Southeast Asia.

• Although buffaloes constitute a smaller proportion of the total bovine population compared to cattle, buffalo have a higher proportion of severe clinical disease and disease duration following HS infection and, therefore, are more likely to have a higher per-animal vaccine revenue contribution in key markets such as India, Pakistan and Bangladesh than cattle.

• Government veterinary programs led the revenue contribution, accounting for nearly 52% in 2025, as the public sector vaccination campaigns assume a major share in the funding of HS vaccine procurement in endemic developing economies, with government departments of animal husbandry implementing mass vaccination programs of cattle and buffaloes in high-risk agroclimatic areas that coincide with the seasonal peaks of disease outbreaks.

Impact of Climate Change and Monsoon Variability on the Hemorrhagic Septicemia Vaccines Market

Climatic conditions and HS outbreak dynamics have commercial implications in the vaccines market. Hemorrhagic septicemia is a highly seasonal disease with outbreaks occurring mainly in the pre-monsoon and monsoon seasons in South and Southeast Asian countries during warm humid conditions, and Flooding, feed deficiency and the increased density of animals in water bodies create a physiological stress that, combined, compromises the immune system of cattle and buffaloes, allowing Pasteurella multocida to become pathogenic.

The intensification of seasonal monsoon variability that is expected with climate change — more extreme wet seasons with longer dry periods, leading to acute feed and water shortages more often and in a wider geographic area—can be expected to put structural demand on the government and private sector for preventive vaccination capacity. At the same time, the highland areas of S Asia and East Africa, which are not currently endemic, are becoming more climatically suitable for HS transmission, which means there is an increasing base of addressable herd populations for HS vaccination programs. In years when vaccine coverage rates in core endemic areas stagnate, these climate-related demand dynamics will further drive the market's underlying growth pattern during the forecast period.

Significant Growth Factors

Expanding Government-Funded National Vaccination Programs in Endemic Countries Generating Institutional Procurement Demand:

The sustained and growing government investment in national, biannual or annual HS vaccination programs for cattle and buffaloes in high-risk areas in South Asia and Sub-Saharan Africa is the biggest structural driver of the hemorrhagic septicemia vaccines market. A single unchecked HS outbreak in an affected village or district could lead to the destruction of the main capital asset for smallholder farming families (the draft animal and milk production) within 24–48 hours, with morbidity and mortality rates reaching 50–100%, depending on the severity of the situation making HS prevention an area of high food security and rural livelihood importance, for which governments cannot survive without taking responsibility — beyond just private market mechanisms.

India has one of the world's most extensive government HS vaccination programs, provided by the national disease control programs under the auspices of the Department of Animal Husbandry and Dairying which centrally tenders hundreds of millions of doses of HS vaccines and delivers these vaccines free of charge or at exceptionally low prices via the state veterinary department network and district veterinary dispensaries to smallholder livestock farmers eligible for vaccination.

India is home to the largest addressable herd base in the world for HS vaccination, with approximately 536 million cattle and buffaloes, of which approximately 109 million buffaloes, as of 2024, are susceptible to HS translating the government's goal to achieve an HS vaccine coverage of 80% or more of the susceptible bovine population in endemic states to an annual target of hundreds of millions of doses. A government HS vaccination program is conducted in different parts of the world, such as Bangladesh, Myanmar, Sri Lanka, Vietnam, Thailand, the Philippines, and Indonesia, with varying levels of scale and coverage, and these programs form the backbone of the global HS vaccines market in terms of revenue.

Pasteurella multocida serotype E:2 (African HS serotype) is a disease that causes substantial mortality, especially in cattle, in Sub-Saharan Africa, including the Democratic Republic of the Congo, Tanzania, Uganda and Ethiopia; funding for HS disease control programs is supplemented by international development organization funds from the African Union's Interafrican Bureau for Animal Resources and the Food and Agriculture Organization of the United Nations and aligned to broader livestock sector development goals.

Rising Economic Awareness of Livestock Loss Costs Driving Private Sector Vaccination Investment in Commercial Farming Systems:

A second structural growth driver is the ongoing and growing expansion of private sector HS vaccine procurement by commercial cattle and buffalo farming enterprises, dairy cooperatives, and organized livestock production companies throughout South and Southeast Asia, which are investing in systematic preventive health programs as their operations expand to meet an increasing demand for milk, beef and buffalo meat, both domestically and internationally.

At a commercial scale, where HS causes mortalities of 50-100% in acute outbreaks, one outbreak event in an unvaccinated commercial herd of 500 USD 1,000-2,000 cattle may incur USD 250,000-1,000,000 in direct losses, losses that are potentially avoidable by implementing vaccination programs at USD 1-5 per animal per year. In addition, the expansion of organized farmer clusters, particularly in India, Bangladesh and Pakistan, where the increasing network of private dairy companies is using systematic HS vaccination as part of comprehensive biosecurity measures to guarantee the continuity and quality of their milk supply chains, or by mandating vaccination as a condition of milk procurement contracts, is leading to its increased inclusion into farmer support programs.

This increased demand for higher specification formalin inactivated HS bacterins, such as oil-adjuvant bacterins with a 12-month immunity duration, that can support annual health calendars without the semi-annual revaccination logistics required by vaccines with aluminum hydroxide as an adjuvant, is driving.

What are the Major Advances Changing the Hemorrhagic Septicemia Vaccines Market Today?

Oil-adjuvant Vaccine Formulation Innovation Extending Immunity Duration and Enabling Single-Dose Annual Protection:

In the recent period, the most notable technical development of significance for the HS vaccine market has been the step-by-step optimization of oil-adjuvant inactivated vaccines, with the introduction of more recent oil-adjuvant systems (Montanide ISA-50V2, Montanide Gel 02) that have paved the way for new-generation vaccines that provide meaningfully better performance attributes than old-formulation mineral oil vaccines, including viscosity, injectability, stability, and immunogenicity duration.

This novel HS oil-adjuvant vaccine has been developed using the bacterial dry weight of 2 mg/mL, which has reduced the dose volume per animal from 5 mL (the standard alum-precipitated dose) down to 2 mL whilst ensuring full sterility, safety and potency compliance with OIE 2017 standards, simplifying the logistics of mass vaccination campaigns in remote endemic areas where handling of animals for repeated doses is a logistical challenge and expensive.

The next-generation, oil-adjuvant HS vaccine pipeline consists of multivalent vaccine combinations with the inclusion of both serotypes of Pasteurella multocida, Asian (B:2) and African (E:2) serotypes, in a single vaccine dose of relevance to livestock farmers and government programs in geographic transition zones between the two serotype-endemic regions. Combined vaccine products containing HS antigens with Clostridium chauvoei (blackleg) and foot-and-mouth disease.

Next-Generation Subunit and Recombinant Vaccine Research Addressing the Limitations of Whole-Cell Bacterin Technology:

The second major area of technical development that will impact the long-term future of the HS vaccines market is the numerous active research and early-stage development options based on subunit, recombinant protein, and nucleic acid vaccine candidates that offer potential solutions to the fundamental limitations of currently available commercially available whole-cell inactivated bacterin vaccines, including serogroup-specific protection coverage, inconsistencies in antigen content between different batches of locally produced vaccines, and the need to maintain a cold chain through a distribution network to remote veterinary posts in rural areas of developing countries where reliable cold chain infrastructure is often lacking.

A study published in April 2024 in the international scientific journal “Frontiers in Immunology” showed that the vaccine formulation of PmSLP3 could offer strong and lasting cross-serogroup protection against HS in cattle challenge trials without the necessity of local strain adaptation, paving the way for a universally available HS vaccine product that is serogroup-independent. Thermostable subunit vaccines based on outer membrane protein candidates are at different stages of laboratory and preclinical testing, with a number of programs in the ICAR-Indian Veterinary Research Institute (IVRI) system in India and several collaborative programs with the International Livestock Research Institute (ILRI) currently underway to develop the subunit HS vaccine formulations capable of surviving distribution logistics without refrigeration in endemic regions.

The live attenuated HS vaccine candidate of the aroA gene-deleted P. multocida B:2 that is metabolically attenuated but still immunologically competent and can successfully stimulate both humoral and cell-mediated immune responses upon intramuscular vaccination has been shown to be effective in cattle challenge trials and is the most advanced live attenuated organism in the process of regulatory review for a commercial HS vaccine.

Digital Livestock Health Management and Cold Chain Technology Improving Vaccine Distribution Reach and Compliance Rates:

The third transformative development in the HS vaccines market is the steady process of digitizing livestock health management systems in key endemic markets (particularly in India, Bangladesh and Vietnam) that is fostering the infrastructure for systematic tracking of HS vaccines at the individual animal level, which would enable targeted identification of unvaccinated animals and the geospatial analysis of vaccination coverage gaps that would focus public sector vaccination resources most effectively on the highest-risk unvaccinated animals.

India's National Animal Disease Control Programme (NADCP), which aims to systematically vaccinate cattle and buffaloes across the country against priority animal diseases, is embedded in digital livestock health management platforms that document vaccination events by individual animal ear-tag IDs, resulting in a national database of HS vaccination coverage which will facilitate evidence-based control efforts and create accountability for public financing of vaccination.

Solar direct refrigerators qualified to store vaccines according to the WHO PQS and passive cold chain carriers which can keep the temperature between 2 and 8°C for 48-72 hours with no active cold chain requirements are helping to close the last-mile cold chain gap that has hampered systematic delivery of vaccines to remote endemic areas, allowing program managers to ensure temperature integrity of oil-adjuvant and aluminum hydroxide-adjuvant bacterin vaccines throughout distribution networks that were previously unable to support systematic cold chain management beyond district veterinary headquarters.

Category Wise Insights

By Vaccine Type

Why Do Oil-adjuvant Inactivated Vaccines Lead the Hemorrhagic Septicemia Vaccines Market?

Oil-adjuvant inactivated vaccines held the largest revenue share of the HS vaccines market accounting for about 47% of the revenue in 2025, owing to the technical performance benefits that have supported gradual replacement of aluminum hydroxide-adjuvant bacterins in government mass vaccination programs and commercial farming practices in which the duration of immunity is a key program planning criterion.

The basic advantage of the oil-adjuvant formulations is their ability to induce a depot effect at the site of injection that leads to prolonged stimulation of B and T lymphocytes resulting in the high-titer, long-lasting antibody response that provides 12–18 months of protection, versus the 6–9 months of protection obtained with alum-precipitated bacterins. The difference in the duration is commercially important as the frequency of revaccination required to keep the herd immunized is different for oil-adjuvant compared with alum-adjuvant vaccines – annual single-dose programs can be used with oil-adjuvant vaccines, while the same level of protection can only be attained with alum-adjuvant vaccines by using semi-annual revaccination, which doubles the logistical requirements and costs.

The Indian government HS vaccination programs have become more and more specific about the selection of oil-adjuvant formulations in central procurement tenders, and the largest domestic manufacturer of veterinary biologicals in India, Indian Immunologicals Limited (IIL), manufactures and supplies oil-adjuvant HS vaccines at scale for the government's distribution.

The new generation Montanide ISA-50V2-adjuvanted formulations which are OIE compliant and achieve the same potency as mineral oil-based formulations yet have reduced volumes of 2 ml per dose are a technical and commercial improvement that is increasingly displacing the previous generation of high-viscosity mineral oil formulations, giving improved ease of administration, reduced adverse reactions at the injection site, and greater compatibility with automated multi-dose syringe equipment used in large-scale herd vaccinations.

By Animal Type

Why Do Buffalo Represent a Disproportionately High Revenue Contribution Relative to Population Share?

The buffalo segment accounted for about 44% of total market revenue in 2025, which is more than its proportion in endemic markets in terms of the proportion of buffalo population to the total bovine population, due to the higher per-animal revenue generation because of greater awareness of HS susceptibility and economic motivation of buffalo owners for systematic vaccination. HS in buffalo is clinically more severe than in cattle and has a shorter disease course (6–24 hours to death after clinical signs appear), with more buffalo having the peracute form of HS with very high mortality rates, even in a small sized unvaccinated buffalo herd, it is unquestionable that it cannot withstand an HS outbreak event.

In India, buffaloes (around 109 million) form the largest buffalo herd in the world and are also important to the dairy economy as providers of high-fat dairy products such as ghee, paneer and khoa, and to the beef export economy as the source of carabeef, which makes India one of the largest beef exporters in the world. Another factor is the high individual animal value of buffalo in Indian markets, USD 500 to 1,500 per animal for mature dairy buffalo compared to the cost of annual HS vaccination, USD 1 to 3 per animal.

By End User

Why Do Government Veterinary Programs Lead the End User Segment?

Overall, government veterinary programs represented around 52% of market revenue in 2025, indicating that public sector institutional procurement is a structural feature of the global HS vaccines market, driven by the major role smallholder livestock farmers play in developing economies, where private veterinary expenditure is limited due to income levels and where the direct link between herd health and rural food security, livelihood stability and agricultural GDP performance provides justification for government investment in HS disease prevention.

The government program procurement takes place mainly through national or state-level, centralized tender processes, with vaccine manufacturers bidding based on technical specification compliance and price, for supply contracts covering millions of doses that offer volume certainty and predictable demand, which is significant for vaccine manufacturers planning production capacity.

The National Animal Disease Control Program in India was introduced in 2019 with the initial central government commitment of USD 1.46 billion for five years and extended, which has been the largest institutional procurement driver of the Indian HS vaccines market as it involves free vaccination of cattle and buffalo against HS and other priority diseases. The movement towards government tender specification of oil-adjuvant vaccines with higher per-dose prices, while it does not reverse the price compression that competitive tendering brings to the commodity end of the bacterin market, is gradually increasing revenues per dose even in the government channel, offsetting some of the price compression.

Report Scope

Regional Analysis

How Big is the Asia Pacific Market Size?

The Asia Pacific hemorrhagic septicemia vaccines market is expected to reach USD 0.36 billion by 2035 at a CAGR of 5.8% from 2026–2035.

Why Does Asia Pacific Dominate the Market?

Asia Pacific accounted for around a 58% share of the global market in 2025, owing to its being the primary endemic zone of the Asian Pasteurella multocida B:2 serotype, the most economically viable strain of the disease and the presence of the world's largest cattle and buffalo population in agroclimatic zones with persistent and seasonal transmission risk due to temperature, humidity and monsoon rainfall.

The estimated share of India in the total global HS vaccine market revenue is 35–40% due to the immense government program procurement, a well-developed domestic vaccine manufacturing base, which includes Indian Immunologicals Limited, Brilliant Bio Pharma, and the Institute of Animal Health and Veterinary Biologicals, and fast-growing demand from the rapidly evolving commercial dairy industry in India.

Myanmar and Sri Lanka have been historically some of the most affected countries by HS per bovine population and have had annual outbreak seasons which create a regular and consistent vaccine demand for the government. Vietnam, Indonesia, Thailand and the Philippines are fast-growing secondary markets due to the growth of their organized cattle and buffalo farming system and the rising government investment in livestock disease prevention programs associated with agricultural development plans.

Why is Sub-Saharan Africa (MEA Region) the Second Most Important Endemic Market?

In 2025, the Middle East and Africa region contributed about 22% market revenue, while the Sub-Saharan Africa region, which is endemic for Pasteurella multocida serotype E:2, was the main region contributing revenue. Sub-Saharan Africa has the highest HS disease burden, and the pastoral and agropastoral production systems of Tanzania, Uganda, Ethiopia, the Democratic Republic of Congo and Kenya have a disproportionately high disease burden and are vulnerable to outbreaks at scale.

HS has been identified as a priority livestock disease for a regional control program in Central and East Africa, and international development funding through these and other bilateral development programs has supplemented national government vaccination budgets in a number of endemic countries, resulting in an increase in HS vaccination demand beyond national government funding resources.

The per capita veterinary expenditure in Sub-Saharan Africa is significantly lower than in the Asia Pacific, and so the revenue contribution per bovine animal protected in Africa is low; however, the number of unvaccinated susceptible animal populations is large, offering very significant growth potential as the scale of the veterinary disease control programs expands with the help of development funding.

Why is the LAMEA Region an Emerging Opportunity?

Total market revenue is estimated to be about 5% of the total for the broader LAMEA region outside of Sub-Saharan Africa, with South American countries (specifically Brazil, Colombia and Bolivia) comprising the largest proportion of the Latin American market, as buffalo are the predominant susceptible animal type in the region.

The commercial buffalo population has been focused on in the Amazon basin, Maranhão and Pará states, and HS outbreaks have been reported due to the presence of Pasteurella multocida strains, with the government funding vaccination programs in these regions. The Middle East is a small part of the LAMEA region, and because HS is not endemic under normal epidemiological conditions in the countries in the Middle East, there are no entry requirements apart from HS vaccination in some jurisdictions in arid-climate countries in the Middle East.

What is the Role of North America and Europe in the Market?

North America and Europe combined make up roughly 15% of the global HS vaccines market revenue because these countries are not endemic regions but are home to the headquarters of the multinational vaccine companies and hotspots of vaccine research and regulatory standards. Although not normally found in North American or European cattle populations, the market demand from these areas is primarily for export production of vaccines for developing countries, procurement by research institutions for challenge studies and evaluation by regulatory authorities.

In HS vaccines, the dominant multinationals, based in North America and Europe, benefit from their global distribution networks, quality management systems, and regulatory skills and have a strong competitive position to address market demand in endemic markets, despite having well-established local competitors in India, Pakistan, and Southeast Asia with a strong cost and market access advantage in their home markets.

Top Players in the Market and Their Offerings

• Zoetis Inc.

• Merck Animal Health

• Boehringer Ingelheim Animal Health

• Elanco Animal Health

• Ceva Santé Animale

• Indian Immunologicals Limited

• Phibro Animal Health Corporation

• Intervac (PVT) Ltd

• Bio-Labs (PVT) Limited

• Brilliant Bio Pharma

• FATRO S.p.A.

• Vetoquinol S.A.

• National Veterinary Research Institute (NVRI)

• Institute of Animal Health and Veterinary Biologicals (IAH&VB)

• Others

Key Developments

In terms of technical and strategic developments, the hemorrhagic septicemia vaccine market has seen significant advancements in the capability of disease control available to government programs and private livestock producers.

• In April 2024, a PmSLP3-based HS vaccine formulation was shown to provide strong cross-serogroup protection against both B:2 and E:2 P. multocida strains in cattle in a peer-reviewed study published in Frontiers in Immunology, a major step towards a broadly applicable HS subunit vaccine that could overcome the serogroup-specific limitation of current whole-cell bacterins and facilitate a uniform global product, rather than having to produce locally adapted formulations.

• In January 2025, ICAR-Indian Veterinary Research Institute, Bengaluru, published research that assessed the comparative protection efficacy of experimental inactivated HS vaccine formulations containing different types of adjuvants (aluminum hydroxide gel, aluminum potassium sulfate, Emulsigen-D, Montanide Gel 02 and Montanide ISA 61) and provided a scientific rationale for choosing adjuvants in next-generation HS vaccine development programs to achieve better immunogenicity and enhanced duration of protection.

• In 2025 (ongoing), the scope and coverage targets for HS mass vaccination campaigns have increased across multiple state governments in India, leading to an increase in volumes of public sector oil-adjuvant HS vaccines being procured by the central government and an increased number of tender opportunities for domestic manufacturers, such as Indian Immunologicals Limited (IIL), as well as for international suppliers looking to tap into the lucrative public sector market for HS vaccines in India.

This trend illustrates the shift of the market from commodity, largely homogeneous bacterins to a more technically segmented competitive market that will offer product differentiation through adjuvant innovation, formulation improvements, and development of new antigen platforms that will allow premium pricing and margin enhancement for manufacturers willing to invest in R&D beyond the commodity bacterin baseline.

The Hemorrhagic Septicemia Vaccines Market is segmented as follows:

By Vaccine Type

• Oil-adjuvant Inactivated Vaccines

  • Mineral Oil-adjuvant Bacterins

  • Montanide ISA-adjuvant Vaccines

  • Multi-emulsion Oil-adjuvant Formulations

• Aluminum Hydroxide-adjuvant Inactivated Vaccines

  • Alum-Precipitated Bacterins

  • Aluminium Hydroxide Gel Vaccines

  • Enriched Alum-Precipitated Formulations

• Live Attenuated Vaccines

  • Intranasal Live Attenuated Strains

  • Intramuscular Live Attenuated Strains (aroA Mutant Platforms)

• Other Vaccine Types

  • Subunit / Recombinant Protein Candidates

  • Combination Multivalent Vaccines

  • Thermostable Formulations

By Animal Type

• Cattle

  • Dairy Cattle

  • Draft Cattle

  • Beef Cattle

• Buffalo

  • Water Buffalo

  • Swamp Buffalo

• Other Animal Types

  • Pigs (Asia-specific outbreak contexts)

  • Sheep & Goats

By End User

• Veterinary Clinics & Hospitals

• Government Veterinary Programs

  • National Disease Control Campaigns

  • District-level Veterinary Dispensaries

• Research Institutes

• Other End Users

  • Commercial Dairy Enterprises

  • Livestock Cooperatives

By Distribution Channel

• Direct Sales (Government Tender Procurement)

• Distributors & Dealers

  • Veterinary Pharmaceutical Distributors

  • Cooperative Society Channels

• Online Retail

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America